Clinical trial
Superficial vein thrombosis (SVT) treated for forty-five days with Rivaroxaban versus Fondaparinux
Evaluation of efficacy and safety of 45 days of rivaroxaban 10 mg vs. fondaparinux 2.5 mg in the treatment of superficial vein thrombosis of risk patients for major VTE complications to prove non-inferiority of oral rivaroxaban treatment
| Category | Value |
|---|---|
| Study start date | 2011-12-23 |